2018, Number 4
<< Back Next >>
Rev Mex Cardiol 2018; 29 (4)
The attempt to demolish the science and practice of preventive cardiovascular medicine. Part I
Addendum to the positioning around the diagnosis and treatment of dyslipidemias of ANCAM and the joint group of associated medical societies
Meaney E, Fernández BCL, Enciso MJM, Ceballos RG, Nájera N, León HFJ, Jiménez OJH, Ramos CMA, Gómez ÁE, Puente BA, Alcocer CA, Guerra LA, Díaz AA
Language: English
References: 79
Page: 173-187
PDF size: 265.07 Kb.
ABSTRACT
This manuscript is an addendum to the positioning around
the diagnosis and treatment of dyslipidemias of ANCAM
and the joint group of associated medical societies, already
published. It is the first part of a wider refl ection aimed
on refute several of the theses and arguments of a group
of clinicians and researchers who question the validity of
the "cholesterol hypothesis", the usefulness and safety
of statins and the most modern inhibitors of proprotein
convertase of subtilisin/kexin type 9 (iPCSK9,) and the
role of saturated fatty acids consumed in the usual diet in
the atherosclerotic risk. This iconoclastic point of view
is dangerous insofar as it undermines the scaffolding
that supports the primary and secondary prevention
of atherosclerosis. In this section of the manuscript,
only the cholesterol hypothesis is discussed. The data
of comparative zoology are reviewed, and several
experimental animal models are analyzed, both supporting
the link between cholesterol and the appearance and
evolution of atherosclerotic lesions. The methodology
and the results of the Study of the 7 Countries are defended and are exposed the numerous epidemiological,
pathological, clinical and interventional evidences, which
in our opinion give a solid sustenance to the cholesterol
hypothesis. Based on this knowledge it is criticized the
LDL cholesterol values currently considered adequate.
Furthermore, the so-called residual risk is considered, as
well as the confl icting evidence about the usefulness of
statins in elderly patients.
REFERENCES
https://www.merriam-webster.com/
Díaz AA, Fernández BC, Enciso MJ, Ceballos RG, Gutiérrez SG, León HF y cols. Posicionamiento en torno al diagnóstico y tratamiento de las dislipidemias. Rev Mex Cardiol. 2018; 29 (s3): s148-s168.
DuBroff R. Cholesterol paradox: a correlate does not a surrogate make. Evid Based Med. 2017; 22: 15-19.
Konstantinov IE, Mejevoi N, Anichkov NM. Nikolai N. Anichkov and his theory of atherosclerosis. Tex Heart Inst J. 2006; 33: 417-423.
Olivier M. Dietary cholesterol, plasma cholesterol and coronary heart disease. Br Heart J. 1976; 38: 214-218.
Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, Watkins BA et al. Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr. 2005; 81: 341-354.
Kones R, Rumana U. Cardiometabolic diseases of civilization: history and maturation of an evolving global threat. An update and call to action. Ann Med. 2017; 49: 260-274.
Finlayson R. Spontaneous arterial disease in animals. Editorial. JRSM. 1983; 76: 811-812.
Hadjiisky P, Bourdillon MC, Grosgogeat Y. Experimental models of atherosclerosis. Contribution, limits and trends. Arch Mal Coeur Vaiss. 1991; 84: 1593-1603.
Kapourchali FR, Surendiran G, Chen L, Uitz E, Bahadori B, Moghadasian MH. Animal models of atherosclerosis. World J Clin Cases. 2014; 2: 126-132.
Emini Veseli B, Perrotta P, De Meyer GRA, Roth L, Van der Donckt C, Martinet W et al. Animal models of atherosclerosis. Eur J Pharmacol. 2017; 816: 3-13.
Ginzinger DG, Wilson JE, Redenbach D, Lewis ME, Clee SM, Excoffon KJ et al. Diet-induced atherosclerosis in the domestic cat. Lab Invest. 1997; 77: 409-419.
Stout C. Atherosclerosis in exotic carnivora and pinnipedia. Am J Pathol. 1969; 57 (3): 673-687.
Farrell AP. Coronary arteriosclerosis in salmon: growing old or growing fast? Comp Biochem Physiol A Mol Integr Physiol. 2002; 132: 723-735.
Takagi M, Ueda M, Becker AE, Takeuchi K, Takeda T. Is the Watanabe heritable hyperlipidemic rabbit a suitable experimental model for percutaneous transluminal coronary angioplasty in humans?: A light microscopic, immunohistochemical and ultrastructural study. Arterioscler Thromb Vasc Biol. 1997; 17: 3611- 3619.
Shiomi M, Ito T, Yamada S, Kawashima S, Fan. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol. 2003; 23: 1239-1244.
Shiomi M, Fan J. Unstable coronary plaques and cardiac events in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits: questions and quandaries. Curr Opin Lipidol. 2008; 19: 631- 636.
Fan J, Challah M, Watanabe T. Transgenic rabbit models for biomedical research: Current status, basic methods and future perspectives. Pathol Int. 1999; 49: 583-594.
Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 1104-1115.
Poledne R, Jurčíková-Novotá L. Experimental models of hyperlipoproteinemia and atherosclerosis. Physiol Res. 2017; 66 (Suppl. 1): S69-S75.
Steinberg D. The cholesterol wars. The skeptics vs. the preponderance of evidence. Elsevier, San Diego, CA, USA, 2007.
McMillan GC. Historical review of research on atherosclerosis. In: Longenecker JB, Kritchevsky D, Drezner MK (editors). Nutrition and Biotechnology in Heart Disease and Cancer. Springer Science+Business Media, LLC. New York 1995, pp. 1-6.
Klurfeld DM. Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch Pathol Lab Med. 1985; 109: 445-449.
Brown MS, Basu SK, Falck JR, Ho YK, Goldstein JL. The scavenger cell pathway for lipoprotein degradation: Specific binding sites mediate the uptake of negatively charged LDL by macrophages. J Supramol Struct. 1980; 13: 67-68.
Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983; 52: 223- 261.
Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol. 2006; 26: 1702-1711.
Bruce Fye W. A historical perspective on atherosclerosis and coronary artery disease. In: Fuster V, Topol EJ, Nabel EG. (Editors). Atherotrombosis and coronary artery disease. Second edition. Lippincott Williams & Wilkins. Philadelphia, USA. 2005, pp. 1-15.
Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976; 295: 369-377.
Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med. 1976; 295: 420- 425.
Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
Libby P. History of discovery: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32: 2045-2051.
Keys Ancel in Kromhout D, Menotti A, Blackburn H (eds.). The seven countries study: a scientific adventure in cardiovascular disease epidemiology. Brouwer Offs. Utrecht, The Netherlands: 1993.
Keys A. Coronary heart disease in seven countries. Circulation. 1970; 41 (S1): 118-139.
Pett KD, Kahn J, Willett WC, Katz DL. Ancel Keys and the Seven Countries Study: an evidencebased response to revisionist histories. White Paper commissioned by the True Health Initiative. http:// www.truehealthinitiative.org
Kahn J. The posthumous assassination of Dr. Ancel Keys. https://www.huffingtonpost.com/entry/theposthumous- assassination-of-dr-ancel-keys_us 20.- (visited, November 2oth, 2018)
Keys A. Atherosclerosis: a problem in newer public health. J Mt Sinai Hosp NY. 1953; 20: 118-139.
Yerushalmy J, Hilleboe H. Fat in the diet and mortality from heart disease: a methodologic note. N Y State Med. 1957; 57 (14): 2343-2354.
De Leiris J, Boucher F, Ducimetiere P, Holdsworth M. The French paradox: fact or fiction ? Expert answers to three key questions. Dialogues Cardiovasc Med. 2008; 13: 183-200.
Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R. The diet and 15-year death rate in the seven countries study. Am J Epidemiol. 1986; 124 (6): 903-915.
Keys A. Epidemiologic aspects of coronary artery disease. J Chronic Dis. 1957; 6: 552-559.
Menotti A, Kromhout D, Blackburn H, Fidanza F, Buzina R, Nissinen A. Food intake patterns and 25-year mortality from coronary heart disease: cross-cultural correlations in the Seven Countries Study. The Seven Countries Study Research Group. Eur J Epidemiol. 1999; 15: 507-515.
Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol. 2002; 1: 1.
Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003; 108: 1070-1077.
Brown MS, Goldstein JL. Heart attacks: Gone with the century? Science. 1996; 272: 629.
Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012; 223 (2): 262-268.
O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol. 2004; 43: 2142-2146.
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32: 1345-1361.
Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM et al. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010; 375: 1634-1639.
Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab. 2014; 28: 353-368.
Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014; 35: 2146-2157.
Patel RS, Scopelliti EM, Olugbile O. The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. Ann Pharmacother. 2018; 52: 1000-1018.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP et al. Effect of evolocumab on progression of coronary disease. The GLAGOV randomized clinical trial in statin-treated patients. JAMA. 2016; 316: 2373- 2384.
Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2017; 4: No. CD011748.
Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the us preventive services task force. JAMA. 2016; 316: 2008-2024.
Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet. 2012; 380: 581-590.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38: 2459-2472.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy S et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. A systematic review and meta-analysis. JAMA. 2016; 316: 1289- 1297.
Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F et al. Effect of statins and nonstatin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. European Heart Journal. 2018; 39: 1172-1180.
Nunes JP. Statins in primary prevention: impact on mortality. A meta-analysis study. Minerva Cardioangiol. 2017; 65: 531-538.
Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey SG et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; (1): CD004816.58.
Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. Emerg Themes Epidemiol. 2015; 12: 14.
Cheng S-J, Yu H-K, Chen Y-C, Chen C-Y, Lien W-C, Yang P-Y et al. Physical activity and risk of cardiovascular disease among older adults. Intern Journal Gerontol. 2013; 7: 133-136.
Veronese N, Sigeirsdottir K, Eiriksdottir G, Marques EA, Chalhoub D, Phillips CL. Frailty and risk of cardiovascular diseases in older persons: The age, gene/environment susceptibility-Reykjavik Study. Rejuvenation Res. 2017; 20: 517-524.
Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults. Uncertainty and the need for more evidence. JAMA. 2016; 316: 1971-1972.
Athyros VG, Katsiki N, Tziomalos K, Gossios TD, Theocharidou E, Gkaliagkousi E et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci. 2013; 9: 418-426.
Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997; 96: 4211-4218.
Rajendran S, Visvanathan R, Tavella R, Weekes AJ, Morgan C, Beltrame JF. In patients with chronic stable angina, secondary prevention appears better in the very old compared to younger patients: the Coronary Artery Disease in gENeral practiCE (CADENCE) Substudy. Heart Lung Circ. 2013; 22: 116-121.
Heart Protection Study Collaborative Group MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-12.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360: 1623-1630.
Ridker PM. The JUPITER Trial. Results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009; 2: 279-285.
Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374: 2021-2031.
Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing. 2010; 39: 674-680.
Savarese G, Gotto AM Jr, Paolillo S, D’Amore C, Losco T, Musella F et al. Benefits of statins in elderly subjects without established cardiovascular disease: a metaanalysis. J Am Coll Cardiol. 2013; 62: 2090-2099.
Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N et al. Lack of an association or an inverse association between low-densitylipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016; 6: e010401.
Eatz T. Letter on Ravnskov review. Available in: https:// bmjopen.bmj.com/
Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet CC. Cigarette smoking and subsequent risk of lung cancer in men and women: analysis of a prospective cohort study. Lancet Oncol. 2008; 9: 649-656.
Félix-Redondo FJ, Grau M, Fernández-Bergés D. Cholesterol and cardiovascular disease in the elderly. Facts and gaps. Aging Dis. 2013; 4: 154-169.
Boone LR, Brooks PA, Niesen MI, Ness GC. Mechanism of resistance to dietary cholesterol. J Lipids. 2011; 2011: 101242.
Tabas I, García-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 2015; 209: 13-22.
Full text